Mimedx Group Inc (MDXG) Stock Price, Quote & News

Company Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techni...

Industry: Biotechnology

Sector: Healthcare

Phone: 770 651 9100

Website: www.mimedx.com

Address:

1775 West Oak Commons Court, NE, Marietta, United States

MitchOnX Nov. 15 at 4:15 PM

$MDXG $MDXG Mimedx Group Inc - 60 Second Analysis - November 15, 2025 #MDXG #... https://youtu.be/mO6mz-ki95M?si=QznXVfkmg7GNqqe_ via @YouTube

0 · Reply

KingHuey203 Nov. 15 at 4:02 PM

$MDXG https://youtu.be/DQTltA9OOjY?si=428TcvqIUSgumq9E

0 · Reply

Tubsmcgee Nov. 15 at 3:57 PM

$MDXG $WAGMI.X

0 · Reply

sage70 Nov. 15 at 3:56 PM

$MDXG Owning this stock has been a nightmare & I do not agree with many of the previous decisions made - especially those made without transparency. But I DO see the ramp to an eventual ‘buyout’ or liquidity event of some kind. If one reads last year’s Annual Report to shareholders you will see that EW Healthcare CLEARLY delineates & declares that its material interests MAY diverge from the interests of common shareholders. & Now the Board has been further packed with cronies, taking free shares, & all of that sticks in my craw. But even with all of that dubious behavior, I presume Mimedx, eventually will be sold at much higher price than $8 per share, so I will wait. GLTA

0 · Reply

sage70 Nov. 15 at 3:54 PM

$MDXG Therefore, eventually, IMO MDXG will become a WC & Surgical Recovery micro-cap medical device company, which will be attractive & practically irresistible as an accretive acquisition to any number of global medical device companies seeking to fit dHACM (& perhaps even mdHACM at a deep discount) into its product line. Unlike others here & elsewhere I do not believe MDXG will entertain a ‘change of control’ until at least late 2027, or even later. I say this based upon a deep reading of this year’s Annual Report to shareholders. BSEM btw just reported earnings DOWN 43% for 3rd q to $10.5 mil. They cited the new impending reimbursement landscape & competition. I remember getting frantic calls from ‘original investors’ re: BSEM eating MDXG’s lunch. Will MDXG’s eventual R.O.I. be what I had hoped & for the reasons I originally had invested in the company? Not remotely. But Capper is making MDXG profitable & perhaps the surgical segment will provide a small premium at sale.

0 · Reply

sage70 Nov. 15 at 3:42 PM

$MDXG As Matt N told me when Capper was first brought in (BTW Matt N previously worked for Bill Hawkins III at Immucor) Joe’s mission was/is to place MDXG back on firm financial footing & to demonstrate to Wall Street that MDXG is a healthy going concern, w/ sound business prospects for the future. & that is what Capper is doing. He is not responsible for the fraud of the crooks in the skin substitute space, nor the blatant lobbying bribery documented by NY Times et al which delayed the CMS decisions so favorable to MDXG TWICE. But it is clear MDXG is squeaky clean via pricing & now has a viable business model where an increase in its volume of sales & its market share (over time obviously) will more than make up for its -$30 per sq cm loss due to new CMS regulated pricing. & THE FACT that CMS LCDs previously determined MDXG has 2 of the 18 approved skin graft products out of more than 200 skin substitute products deemed lacking in sufficient research will prove a material advantage.

1 · Reply

sage70 Nov. 15 at 3:10 PM

$MDXG I invested in MDXG primarily based upon a belief in a) the remarkable potentially disruptive therapeutic powers of both dHACM & most especially of MDXG’s mdHACM for KOA, worth billions to Big Pharma IMO, if it had been allowed to complete a redo of its second Phase 2 trial (ancient & painful history at this point) & b) a belief in Pete Petit as a remarkable & proven healthcare CEO, who was also of exceptional integrity, & a CEO who would guide Mimedx to an eventual liquidity event with a substantial BIOTECH premium (which are demonstrably higher than Medical Device premia). This is all ancient history & still extremely painful even to recall on 11/15/25. But if you read the Annual Shareholders report of year before last, it was OBVIOUS the BoD, based upon specious reasoning & rationales IMO, was getting ready to deep six the regen med KOA division, writing off $50 million in R & D, & once again returning MDXG to solely & merely a medical device company no longer a true biotech.

0 · Reply

sage70 Nov. 15 at 3:05 PM

$MDXG Since there are only about a dozen MDXG ‘stakeholders’ posting on, or reading this message board, it is not as if anything posted here will ever influence anyone or anything in regard to Mimedx’s stock price or the company’s strategic priorities, or will affect any decisions made by the all-powerful, dominant, & determining members of the Board of Directors (because, make no mistake, it is not Joe Capper, nor is it Kathy Behrens who will decide when & for how much & to whom MDXG is sold). Therefore, why post at all? Like some of you here, I have been invested in Mimedx for well over a decade (14 years, actually) and more relevantly, I FOOLISHLY went ‘all in’ in 2017.

0 · Reply

jmdaddy Nov. 14 at 5:37 AM

$MDXG Well still hoping we see a late week rally.

0 · Reply

FinancialScience Nov. 13 at 8:14 PM

$MDXG this has aged well

0 · Reply

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Nov 10, 2025, 4:01 PM EST - 5 days ago

MIMEDX to Participate in Upcoming Investor Conferences

Nov 4, 2025, 9:56 AM EST - 11 days ago

MiMedx: Breakout Setup Into A Policy Overhaul

Nov 3, 2025, 9:15 AM EST - 12 days ago

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

Oct 29, 2025, 6:56 PM EDT - 17 days ago

MiMedx Group, Inc. (MDXG) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:01 PM EDT - 17 days ago

MIMEDX Announces Record Revenue for Third Quarter 2025

Oct 15, 2025, 8:00 AM EDT - 4 weeks ago

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29

Oct 6, 2025, 9:28 AM EDT - 5 weeks ago

MIMEDX Announces Launch of EPIXPRESS®

Sep 3, 2025, 8:00 AM EDT - 2 months ago

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

Jul 30, 2025, 11:01 PM EDT - 3 months ago

MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:01 PM EDT - 3 months ago

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

Jul 30, 2025, 8:00 AM EDT - 3 months ago

MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

Jul 16, 2025, 8:00 AM EDT - 4 months ago

MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

Jul 15, 2025, 9:15 AM EDT - 4 months ago

MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

May 6, 2025, 8:00 AM EDT - 6 months ago

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:30 AM EDT - 6 months ago

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

Apr 30, 2025, 9:52 PM EDT - 7 months ago

MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:01 PM EDT - 7 months ago

MIMEDX Announces First Quarter 2025 Operating and Financial Results

Apr 10, 2025, 4:01 PM EDT - 7 months ago

MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

Feb 27, 2025, 8:00 AM EST - 9 months ago

MIMEDX to Present at TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 10:50 PM EST - 9 months ago

MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 9 months ago

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

Nov 14, 2024, 9:15 AM EST - 1 year ago

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

Oct 30, 2024, 9:38 PM EDT - 1 year ago

MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

Oct 14, 2024, 8:00 AM EDT - 1 year ago

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

Oct 8, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

Oct 1, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

Sep 11, 2024, 1:03 PM EDT - 1 year ago

EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

Sep 4, 2024, 4:23 PM EDT - 1 year ago

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

Aug 26, 2024, 9:30 AM EDT - 1 year ago

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

Jul 31, 2024, 9:10 PM EDT - 1 year ago

MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:02 PM EDT - 1 year ago

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

Jul 31, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces Second Quarter 2024 Operating and Financial Results

Jul 22, 2024, 8:10 AM EDT - 1 year ago

MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports

Jun 26, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

Apr 30, 2024, 9:33 PM EDT - 1 year ago

MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript

Apr 30, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces First Quarter 2024 Operating and Financial Results

Apr 16, 2024, 8:00 AM EDT - 1 year ago

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

Mar 20, 2024, 7:00 AM EDT - 1 year ago

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

Feb 28, 2024, 8:46 PM EST - 1 year ago

MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 1 year ago

MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

Feb 20, 2024, 8:00 AM EST - 1 year ago

MIMEDX to Present at TD Cowen 44th Annual Health Care Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28

Jan 22, 2024, 8:00 AM EST - 1 year ago

MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing

Jan 12, 2024, 4:00 PM EST - 2 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

Jan 11, 2024, 12:54 PM EST - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

Dec 29, 2023, 7:01 PM EST - 2 years ago

MiMedx reports US FDA warning letter for Axiofill, shares drop

MitchOnX Nov. 15 at 4:15 PM

$MDXG $MDXG Mimedx Group Inc - 60 Second Analysis - November 15, 2025 #MDXG #... https://youtu.be/mO6mz-ki95M?si=QznXVfkmg7GNqqe_ via @YouTube

0 · Reply

KingHuey203 Nov. 15 at 4:02 PM

$MDXG https://youtu.be/DQTltA9OOjY?si=428TcvqIUSgumq9E

0 · Reply

Tubsmcgee Nov. 15 at 3:57 PM

$MDXG $WAGMI.X

0 · Reply

sage70 Nov. 15 at 3:56 PM

0 · Reply

sage70 Nov. 15 at 3:54 PM

0 · Reply

sage70 Nov. 15 at 3:42 PM

1 · Reply

sage70 Nov. 15 at 3:10 PM

0 · Reply

sage70 Nov. 15 at 3:05 PM

0 · Reply

jmdaddy Nov. 14 at 5:37 AM

$MDXG Well still hoping we see a late week rally.

0 · Reply

FinancialScience Nov. 13 at 8:14 PM

$MDXG this has aged well

0 · Reply

GlobalInsights Nov. 13 at 1:56 PM

$MDXG https://investors.mimedx.com/news-releases/news-release-details/mimedx-provides-update-epieffectr-randomized-controlled-trial

1 · Reply

njbugatti Nov. 13 at 1:54 PM

$MDXG https://internationaljournaloftissuerepair.com/index.php/ijtr/article/view/26

0 · Reply

sage70 Nov. 11 at 5:14 PM

$MDXG Hedge Funds Weigh In On MDXG Several hedge funds & institutional investors recently made changes to their positions in the co. Trigran Investments raised its position in shares of MDXG by 10.4% 2nd q. Trigran Investments Inc. now owns 8,390,458 shares of co's stock valued at $51,266,000 after buying an additional 790,901 shares in last quarter. 1st Light Asset Management raised its position in MDXG by 3.3% during first q. 1st Light now owns 3,453,074 shares of co.s stock valued at $26,243,000 after purchasing an additional 109,213 shares last q. Punch & Associates raised its position in MDXG by 0.7% during 1st quarter. Punch & Associates Investment Management Inc. now owns 1,738,678 shares of co's stock valued at $13,214,000 after purchasing an additional 12,414 shares in last q. Millennium Management raised its shares of MDXG by 93.9% during 1st quarter. Millennium now owns 1,230,984 shares of co's stock worth $9,355,000 after buying additional 596,016 shares in last quarter.

0 · Reply

sage70 Nov. 11 at 5:06 PM

$MDXG There are a number of 'original investors' who are inveterate Mimedx perma bears because they are bitter at how Pete Petit was handled, & they lost A LOT of money selling their millions of MDXG shares at one of its many nadirs. Their confirmation bias is off the charts & they have been chicken littling Mimedx's demise with every new 'threat' - from silk worm allografts to BSEM or STIM LABS et al. that would wipe Mimedx out. I read FOUR analyst reports & they EACH posited MDXG eventually would prevail & grow & improve its balance sheet - while also acknowledging a likely shaky first two quarters next year given the new landscape. JUST as Joe Capper acknowledged to each analyst in this previous earnings call. MDXG is now a med device micro cap subject to regulation, commoditization,& competition -not why I invested for the KOA - but despite ur assertion that old SOC would soak up revs- Epifix is still best in class & BEAT SOC: healing better & more quickly. Time will tell.

0 · Reply

Bmelord12 Nov. 11 at 3:40 PM

$MDXG I spoke to one of the original investor in MDXG to get his perspective on 2026 revenue and earnings guidance. The average est for revenue and eps growth in 2026 is 2.0% and -6.0% respectively! He said analyst and management are reluctant to provide guidence for 2026 given the pending new rules for advanced wound care products. FYi, I wanted to know what was behind analyst assumptions!!

0 · Reply

Mobagri Nov. 11 at 3:17 PM

$MDXG ORGO keeps going up

0 · Reply

Mobagri Nov. 7 at 2:51 PM

$MDXG are you sure?

0 · Reply

sage70 Nov. 7 at 1:35 PM

$MDXG Just to be accurate, Northland Capital only revised their 2026 projected EPS down to 34c from their 2025 EPS estimate of 40c. But they also retained their $12 price target & titled their report, "Poised for a Breakout". This was the precise assessment & sentiment of every other analyst who covers MDXG (each reiterated a $12 pt) & who listened to the Earnings Call on 10/29. BTW the Mizuho analyst also reiterated his $20 'bull case' pt, depending upon how much market share MDXG accrues next year when all (or many) of the bad actors are removed from this Wound Care skin substitute competitive landscape because of their fraudulent unsustainable $3,000 per sq cm business model. Capper demonstrably is turning this co. around, making it an accretive cash cow, eventually, with a strong WC/Surgical I.P. , an I.P. which is highly disruptive in the surgical space. Remember also, despite his lucrative options package, Capper already has bought out of pocket 300,000 shares in the mid-sixes.

3 · Reply

njbugatti Nov. 6 at 7:07 PM

$MDXG northland cut 2026 eps from 34c to 20c based upon cms ruling. i havent seen the report just heard it. Capper&Co just need to keep executing like they just did in Q3.

2 · Reply

Telluwhat Nov. 6 at 6:54 PM

$MDXG 💩same old shit.

0 · Reply

CharlyBue Nov. 6 at 5:03 PM

$MDXG damn fraudsters -8% 🤮

0 · Reply

GlobalInsights Nov. 6 at 4:01 PM

$MDXG Couldn’t break $8 so quant algorithms taking it down to $$7.50

1 · Reply

Market Cap	1.09B
Revenue (ttm)	348.88M
Net Income (ttm)	42.42M
EPS (ttm)	N/A
PE Ratio	19.66
Forward PE	20.47
Profit Margin	12.16%
Debt to Equity Ratio	0.01

Volume	735,600
Avg Vol	844,900
Day's Range	N/A - N/A
Shares Out	148.10M
Stochastic %K	21%
Beta	1.70
Analysts	Strong Sell
Price Target	$12.20